249 related articles for article (PubMed ID: 16304639)
1. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway.
Miellot A; Zhu R; Diem S; Boissier MC; Herbelin A; Bessis N
Eur J Immunol; 2005 Dec; 35(12):3704-13. PubMed ID: 16304639
[TBL] [Abstract][Full Text] [Related]
2. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
3. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
[TBL] [Abstract][Full Text] [Related]
4. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide.
Chiba A; Oki S; Miyamoto K; Hashimoto H; Yamamura T; Miyake S
Arthritis Rheum; 2004 Jan; 50(1):305-13. PubMed ID: 14730629
[TBL] [Abstract][Full Text] [Related]
5. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.
Coppieters K; Van Beneden K; Jacques P; Dewint P; Vervloet A; Vander Cruyssen B; Van Calenbergh S; Chen G; Franck RW; Verbruggen G; Deforce D; Matthys P; Tsuji M; Rottiers P; Elewaut D
J Immunol; 2007 Aug; 179(4):2300-9. PubMed ID: 17675491
[TBL] [Abstract][Full Text] [Related]
6. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis.
Kaieda S; Tomi C; Oki S; Yamamura T; Miyake S
Arthritis Rheum; 2007 Jun; 56(6):1836-45. PubMed ID: 17530712
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
8. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S; Paoletti T; Panza L; Lombardi G
Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
[TBL] [Abstract][Full Text] [Related]
9. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
10. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma.
Hachem P; Lisbonne M; Michel ML; Diem S; Roongapinun S; Lefort J; Marchal G; Herbelin A; Askenase PW; Dy M; Leite-de-Moraes MC
Eur J Immunol; 2005 Oct; 35(10):2793-802. PubMed ID: 16180255
[TBL] [Abstract][Full Text] [Related]
11. In vivo activation of invariant V alpha 14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity.
Lisbonne M; Hachem P; Tonanny MB; Fourneau JM; Sidobre S; Kronenberg M; Van Endert P; Dy M; Schneider E; Leite-de-Moraes MC
Eur J Immunol; 2004 May; 34(5):1381-8. PubMed ID: 15114671
[TBL] [Abstract][Full Text] [Related]
12. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis.
Kelchtermans H; Geboes L; Mitera T; Huskens D; Leclercq G; Matthys P
Ann Rheum Dis; 2009 May; 68(5):744-50. PubMed ID: 18480308
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.
Chen S; Ndhlovu LC; Takahashi T; Takeda K; Ikarashi Y; Kikuchi T; Murata K; Pandolfi PP; Riccardi C; Ono M; Sugamura K; Ishii N
Eur J Immunol; 2008 Aug; 38(8):2229-40. PubMed ID: 18624295
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production.
Lo CK; Lam QL; Sun L; Wang S; Ko KH; Xu H; Wu CY; Zheng BJ; Lu L
Arthritis Rheum; 2008 Sep; 58(9):2700-11. PubMed ID: 18759269
[TBL] [Abstract][Full Text] [Related]
15. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
16. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
17. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
18. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity.
Molling JW; Moreno M; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
J Immunol Methods; 2007 Apr; 322(1-2):70-81. PubMed ID: 17343874
[TBL] [Abstract][Full Text] [Related]
19. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.
Miellot-Gafsou A; Biton J; Bourgeois E; Herbelin A; Boissier MC; Bessis N
Immunology; 2010 Jun; 130(2):296-306. PubMed ID: 20113367
[TBL] [Abstract][Full Text] [Related]
20. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
